Rozanolixizumab-noli: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 May 2024

  • curprev 14:2214:22, 23 May 2024Muhammad Waleed talk contribs 8,759 bytes +5,524 No edit summary
  • curprev 12:4312:43, 23 May 2024Muhammad Waleed talk contribs 3,235 bytes +3,235 Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac..."